/PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at the International Congress of Parkinson's...

XellSmart presented nine-person Phase I XS411 results and completed enrollment in a 30-person randomized Phase II Parkinson's study.

/PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at the International Congress of Parkinson's...

XellSmart presented new clinical findings on their innovative Parkinson's Disease cell therapy at the MDS conference, marking significant advanced treatments.

A paradigm shift in the way we treat spinal injuries is now in sight, with the world's first regenerative cell therapy being granted approval for a registrational Phase I clinical trial. It's a histor...

/PRNewswire/ -- In May 2025, XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. officially announced that XellSmart-developed off-the-shelf allogeneic...

SUZHOU, China, March 2, 2026 /PRNewswire/ — In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the […]

Allegato: 1 immagine Per la prima volta nella storia della medicina, una terapia cellulare punta a rigenerare completamente il midollo spinale danneggiato. XellSmart ha ottenuto l'approvazione simult...

Midollo spinale riparato per la prima volta: cellule staminali "off-shelf" promettono di sconfiggere definitivamente la paralisi

The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for XS-411, a stem cell-based therapy developed by Xellsmart for Parkinson’s disease, clearing the way for a Phase 1 clinical trial. The company also received...

XellSmart's innovative cell therapy XS411 for Parkinson's has received Fast Track Designation from the FDA, highlighting its potential in treatment.

XellSmart embarks on a Phase II trial for XS411, a groundbreaking cell therapy for Parkinson's, after promising Phase I results. This innovative therapy aims to enhance patient outcomes significantly.

XellSmart secures its fourth consecutive IND clearance from the US FDA and China's NMPA for a new cell therapy targeting MSA-P, showcasing its innovative approach.

XellSmart Biomedical has received FDA clearance for three groundbreaking allogeneic iPSC-derived cell therapies aimed at treating Parkinson's disease, spinal cord injuries, and ALS, marking a significant advancement in biomedicine.

XellSmart's innovative allogeneic iPSC-derived cell therapy has received FDA approval for clinical trials, offering hope for spinal cord injury treatment.

XellSmart Biopharmaceutical has achieved FDA approval for its innovative cell therapies aimed at treating Parkinson's Disease and ALS, moving towards clinical trials.

척수손상치료의혁명예고!세계최초재생세포치료제,인체실험돌입 전세계1,500만명이상의삶을짓누르는척수손상(SCI)치료에획기적인전환점이마련됐다.

XellSmart's proprietary off-the-shelf iPSC-derived cell therapy XS411 receives Fast Track Designation from the US FDA, marking a key milestone for its global clinical development across China and the United States. SHANGHAI and SUZHOU, China, Aug. 4, 2026 /PRNewswire/ -- On July 28, 2026,...

SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's...